Welcome

Welcome Maryland and D.C. Society of Clinical Oncology Members to our newly established social media website. The purpose of the website is to encourage communication among the MDCSCO membership on topics that are of interest and importance to our members.

The mission of the Maryland and District of Columbia Society of Clinical Oncology (MDCSCO) is to improve the quality and delivery of care of medical oncology in Maryland and the District of Columbia, to educate public government and insurance carriers about appropriate prevention of cancer and current therapeutic options for our patients with cancer and to promote appropriate standards of the care of oncology including participation in cancer research.

MDCSCO is undergoing a reorganization to improve our effectiveness. This will include the development of the Practice Committee, the Advocacy Policy Committee and the Program Committee. The Practice Committee is centered around issues related to access to care, for advocacy with regard to Medicare and Medicaid as well as other insurance carriers. The primary focus of this committee is to provide care for all patients for appropriate oncology services as well as reimbursement for these services.

We look forward to increased member participation as well as ideas on new initiatives to make our organization relevant and interesting.

Paul Celano, MD FACP
President, Maryland DC Society of Clinical Oncology

This project was partially funded by a grant from ASCO.

OUR CORPORATE MEMBERS
Diamond Members
Celgene
 
Emerald Members
Amgen
 Sandoz
Sandozlogo1
Platinum Members
Bayer
Eli Lilly Pharmaceuticals

Eli Lilly Pharmaceuticals
Infinity Pharmaceuticals
infinity-pharma-logo-2015_175
Merck
mercklogo1
Novartis Oncology
novartis
Onyx
Pfizer
TEVA
tevalogo
Gold Members
Amerisource Bergen
amerisourcebergen
AstraZeneca
astrazenecalogo
Boehringer-Ingelheim
Bristol-Myers Squibb

EMD Serono

Genentech
Incyte

incytelogo
OncoPlexDx
oncoplex
Pharmacyclicspharmacyclics1 Prometheus Labs
PRMlogoNestleTag
Seattle Genetics
seattlegenetics
Takeda Oncology
takeda_logo
Taiho OncologyTaihoOncologyLogosm

Silver Members
Eisai
Foundation Medicinefoundation-medicine
Gilead Sciencesgilead3 Helsinn
Jazz Pharmaceuticals
jazzlogo1
  Sanofi

 

National Webcast – Keytruda as a Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description more »

Read more

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

KENILWORTH, N.J., Aug. 5, 2016 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with more »

Read more